Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients

Anticancer Research

Volumn 31, Issue 2, 2011, Pages 711-718

  Halon, Agnieszka ^a   Nowak Markwitz, Ewa ^b   Maciejczyk, Adam ^c   Pudelko, Marek ^c   Gansukh, Tserenchunt ^d   Györffy, Balázs ^e,f   Donizy, Piotr ^a   Murawa, Dawid ^g   Matkowski, Rafal ^a,c   Spaczynski, Marek ^b   Lage, Hermann ^f   Surowiak, Pawel ^a,c,f  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Dolnoslaskie Centrum Onkologii Wroclaw   (Poland)

^d MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f Charité Campus Benjamin Franklin Medical Center   (Germany)

^g Wielkopolska Cancer Center   (Poland)

Author keywords

Cisplatin; Estrogen receptor beta; Immunohistochemistry; Ovarian cancer; Prognostic factor

Indexed keywords

CISPLATIN; ESTROGEN RECEPTOR BETA;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL LINE; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LAPAROTOMY; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TREATMENT RESPONSE;

CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL RATE;

EID: 79953233108     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C and Vergote I: Ovarian cancer. Crit Rev Oncol Hematol 60: 159-179, 2006.
2. Gatta G, Capocaccia R, De Angelis R, Stiller C, Coebergh JW the EUROCARE Working Group: Cancer survival in European adolescents and young adults. Eur J Cancer 39: 2600-2610, 2003. (Pubitemid 37468301)
3. Pearce ST and Jordan VC: The biological role of estrogen receptors α and β in cancer. Crit Rev Oncol Hem 50: 3-22, 2004. (Pubitemid 38501614)
4. Lazennec G: Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Letters 231: 151-157, 2006.
5. Cunat S, Hoffmann P and Pujol P: Estrogens and epithelial ovarian cancer. Gynecol Oncol 94: 25-32, 2004.
6. Bardin A, Hoffmann P, Boulle N, Katsaros D, Vignon F, Pujol P and Lazennec G: Involvement of estrogen receptor β in ovarian carcinogenesis. Cancer Res 64: 5861-5869, 2004. (Pubitemid 39095587)
7. Lindgren PR, Cajander S, Bäckström T, Gustafsson JA, Mäkelä S and Olofsson JI: Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell End 221: 97-104, 2004. (Pubitemid 38829727)
8. Li AJ, Baldwin RL and Karlan BY: Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures. Am J Obstet Gynecol 189: 22-27, 2003. (Pubitemid 36886519)
9. Chan KK, Wei N, Liu SS, Xiao-Yun L, Cheung AN and Ngan HY: Estrogen receptor subtypes in ovarian cancer. A clinical correlation. Obstet Gynecol 111: 144-151, 2008
10. Jordan VC, Gapstur S and Morrow M: Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. J Natl Cancer Inst 93: 1449-1457, 2001. (Pubitemid 32982673)
11. Kurebayashi J: Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 10: 112-119, 2003.
12. Harries M and Kaye SB: Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs 10: 1715-1724, 2001.
13. McClay EF, Albright KD, Jones JA, Christen RD and Howell SB: Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br J Cancer 70: 449-452, 1994. (Pubitemid 24268546)
14. Materna V, Liedert B, Thomale J and Lage H: Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer 115: 393-402, 2005. (Pubitemid 40663743)
15. Materna V, Stege A, Surowiak P, Priebsch A and Lage H: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun 348: 153-157, 2006. (Pubitemid 44163494)
16. Kowalski P, Surowiak P and Lage H: Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther 11: 508-522, 2005.
17. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dolinska-Krajewska B, Gebarowska E, Dietel M, Zabel M and Lage H: ABCC2 (MRP2, cMOAT) Can Be Localized in the Nuclear Membrane of Ovarian Carcinomas and Correlates with Resistance to Cisplatin and Clinical Outcome. Clin Cancer Res 12: 7149-7158, 2006.
18. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M and Lage H: Resistance prediction profile for eleven anticancer agents at clinical concentrations based on the gene expression pattern of thirty cell lines. Int J Cancer 118: 1699-1712, 2006.
19. UICC TNM Classification of malignant tumors. Sobin LH, Wittekind Ch (eds). Wiley-Liss, New York, 1997.
20. Shimizu Y, Kamoi S, Amada S, Akiyama F and Silverberg SG: Toward the development of a universal grading system of ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Cancer 82: 893-901, 1998. (Pubitemid 28104169)
21. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H and Zabel M: Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapsed ovarian cancer tissue samples. Histol Histopathol 25: 131-139, 2006.
22. Materna V, Surowiak P, Markwitz E, Spaczynski M, Drag-Zalesinska M, Zabel M and Lage H: Expression of factors involved in regulation of DNA mismatch repair- and apoptosis pathways in ovarian cancer patients. Oncol Rep 17: 505-516, 2007.
23. Surowiak P, Materna V, Maciejczyk A, Kaplenko I, Spaczynski M, Dietel M, Lage H and Zabel M: CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients. Anticancer Res 26(6C): 4943-4948, 2006. (Pubitemid 46032139)
24. Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G and Ortmann O: Estrogen receptor β1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193: 421-433, 2007. (Pubitemid 47028693)
25. Münstedt K, Steen J, Knauf AG, Buch T, von Georgi R and Franke FE: Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 89: 1783-1791, 2000.
26. Fujimoto J, Hirose R, Sakaguchi H and Tamaya T: Clinical significance of expression of estrogen receptor alpha and beta mRNAs in ovarian cancers. Oncology 58: 334-341, 2000. (Pubitemid 30265344)
27. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Muñoz A and Mor G: Absence of estrogen receptor-β expression in metastatic ovarian cancer. Obstet Gynecol 96: 417-421, 2000.
28. Park SH, Cheung LW, Wong AS and Leung PC: Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor a. Mol Endocrinol 22: 2085-2098, 2008.
29. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG; European Organization for Research and Treatment of Cancer: New guidelines to evaluate the response to treatment in solid rumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3): 205-216, 2000.